Companies

Apex court quashes Bayer’s plea on Nexavar licence

Our Bureau Hyderabad | Updated on December 12, 2014 Published on December 12, 2014


In what could be a positive development for Natco Pharma, the Supreme Court on Friday quashed a special leave petition filed by Bayer Corporation challenging grant of compulsory licence to Natco for its liver/kidney cancer drug Sofrafenib.

This was stated by Natco in a release. Bayer had appealed to the Supreme Court following a setback it received in the Bombay High Court in July 2014.

Sorafenib Tosylate is now being sold under brand name Nexavar by Bayer. In March 2012, Natco Pharma secured compulsory licence from the Government of India to make a generic of Nexavar.

With this, Natco would be able to bring down the price significantly. While Natco’s drug costs ₹8,880 for a pack of 120 tablets, Bayer is priced at ₹2.84 lakh.

Published on December 12, 2014

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.